Drug Trial Radar · NCT05197270
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
215
Planned (sponsor's estimate)
Start
Dec 9, 2021
Primary completion
Mar 2027
Study completion Jan 2031
Sponsor
- Lead sponsor
- 4D Molecular TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
Interventions
4D-150 IVTBiological
4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept
Aflibercept IVTBiological
Commercially available Active Comparator Other Name: Eylea
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant changes in safety parametersTime frame: 52 weeks
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
Barnet Delaney Perkins Eye Center
Phoenix, Arizona · Recruiting
California Retina Consultants
Oxnard, California · Recruiting
Retinal Consultants Medical Group
Sacramento, California · Recruiting
Colorado Retina Associates
Lakewood, Colorado · Recruiting
Rand Eye Institute
Deerfield Beach, Florida · Suspended
Retina Group of Florida
Fort Lauderdale, Florida · Recruiting
Retina Vitreous Consultants, LLP DBA Retina Group of Florida
Fort Lauderdale, Florida · Active not recruiting
Vitreo Retinal Associates
Gainesville, Florida · Recruiting
Florida Eye Associates
Melbourne, Florida · Recruiting
Retinal Specialty Institute
Pensacola, Florida · Recruiting
Retina Vitreous Associates of Florida
Tampa, Florida · Recruiting
University Retina and Macula Associates
Oak Forest, Illinois · Recruiting
Retina Partners Midwest
Carmel, Indiana · Recruiting
Cumberland Valley Retina Consultants
Hagerstown, Maryland · Recruiting
Ophthalmic Consultants of Boston & Boston Eye Surgery and Laser Center
Boston, Massachusetts · Recruiting
Sierra Eye Associates
Reno, Nevada · Recruiting
Western Carolina Retinal Associates
Asheville, North Carolina · Withdrawn
Verum Research, LLC
Eugene, Oregon · Recruiting
Mid Atlantic Retina
Bethlehem, Pennsylvania · Recruiting
Palmetto Retina Center, LLC
West Columbia, South Carolina · Recruiting
Tennessee Retina
Nashville, Tennessee · Recruiting
Austin Clinical Research
Austin, Texas · Recruiting
Valley Retina Institute, PA
McAllen, Texas · Recruiting
Retina Consultants of Texas
The Woodlands, Texas · Withdrawn
Pacific Northwest Retina LLC
Bellevue, Washington · Withdrawn
Emanuelli Research and Development Center, LLC
Arecibo, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.